DE4447484C2 - Mittel zur Hemmung von Apoptose - Google Patents

Mittel zur Hemmung von Apoptose

Info

Publication number
DE4447484C2
DE4447484C2 DE4447484A DE4447484A DE4447484C2 DE 4447484 C2 DE4447484 C2 DE 4447484C2 DE 4447484 A DE4447484 A DE 4447484A DE 4447484 A DE4447484 A DE 4447484A DE 4447484 C2 DE4447484 C2 DE 4447484C2
Authority
DE
Germany
Prior art keywords
apo
compound
tat
receptor
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE4447484A
Other languages
German (de)
English (en)
Other versions
DE4447484A1 (de
Inventor
Peter Prof Dr Krammer
Klaus-Mich Dr Debatin
Michael Westendorp
Rainer Dr Frank
Jens Dr Dhein
Henning Walczak
Eckart Knipping
Kirstin Dr Stricker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Priority to DE19944412177 priority Critical patent/DE4412177C1/de
Priority to DE4447484A priority patent/DE4447484C2/de
Priority claimed from DE19944412177 external-priority patent/DE4412177C1/de
Publication of DE4447484A1 publication Critical patent/DE4447484A1/de
Application granted granted Critical
Publication of DE4447484C2 publication Critical patent/DE4447484C2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DE4447484A 1994-04-08 1994-04-08 Mittel zur Hemmung von Apoptose Expired - Lifetime DE4447484C2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE19944412177 DE4412177C1 (de) 1994-04-08 1994-04-08 Hemmer von Apoptose
DE4447484A DE4447484C2 (de) 1994-04-08 1994-04-08 Mittel zur Hemmung von Apoptose

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19944412177 DE4412177C1 (de) 1994-04-08 1994-04-08 Hemmer von Apoptose
DE4447484A DE4447484C2 (de) 1994-04-08 1994-04-08 Mittel zur Hemmung von Apoptose

Publications (2)

Publication Number Publication Date
DE4447484A1 DE4447484A1 (de) 1995-10-26
DE4447484C2 true DE4447484C2 (de) 1997-07-17

Family

ID=6514949

Family Applications (1)

Application Number Title Priority Date Filing Date
DE4447484A Expired - Lifetime DE4447484C2 (de) 1994-04-08 1994-04-08 Mittel zur Hemmung von Apoptose

Country Status (8)

Country Link
US (1) US20070207160A1 (https=)
EP (1) EP0705278B1 (https=)
JP (2) JP3778453B2 (https=)
AT (1) ATE255129T1 (https=)
DE (1) DE4447484C2 (https=)
DK (1) DK0705278T3 (https=)
ES (1) ES2211899T3 (https=)
WO (1) WO1995027735A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029350A1 (en) 1995-03-20 1996-09-26 Sumitomo Electric Industries, Ltd. MONOCLONAL ANTIBODY REACTING SPECIFICALLY WITH Fas LIGAND AND PROCESS FOR PRODUCING THE SAME
WO1996040041A2 (en) * 1995-06-07 1996-12-19 Chiron Corporation Antibodies to fas antigen capable of inhibiting apoptosis
US6096312A (en) * 1995-06-30 2000-08-01 Mochida Pharmaceutical Co., Ltd. Agent for suppressing a reduction of CD4+ lymphocytes
JPH09124509A (ja) * 1995-10-27 1997-05-13 Sumitomo Electric Ind Ltd 肝炎治療剤
DE19544333C2 (de) * 1995-11-28 1998-12-10 Deutsches Krebsforsch Verfahren zur Beurteilung der Aktivität von Arzneistoffen
AU2814897A (en) * 1996-04-25 1997-11-12 T Cell Sciences, Inc. Method of isolating regulators of t cell activation
GB9703276D0 (en) * 1997-02-17 1997-04-09 Screaton Gavin R Materials and methods relating to the protection of useful immune cells
AU1288099A (en) * 1997-10-30 1999-05-24 Cornell Research Foundation Inc. A method of inhibiting an immune response to a recombinant vector
EP1447093A1 (en) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
CA2520138C (en) 2003-03-26 2017-05-23 Apogenix Gmbh Improved fc fusion proteins
ES2523992T3 (es) 2006-12-28 2014-12-03 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts La neutralización de la actividad de CD95 bloquea la invasión de células de glioblastoma in vivo
EP2540740B1 (en) 2008-06-17 2014-09-10 Apogenix GmbH Multimeric TNF receptors
US11369572B2 (en) * 2009-07-21 2022-06-28 Queen Mary & Westfield College Fas (Apo-1,CD95) targeted platforms for intracellular drug delivery
RU2652348C2 (ru) 2012-07-18 2018-04-25 Аподжиникс Аг Ингибиторы сигнального пути cd95 для лечения мдс
EP3076179A1 (en) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
CA3049165A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
BR112019013940A2 (pt) 2017-01-06 2020-02-11 Iovance Biotherapeutics, Inc. Método de tratar um câncer com uma população de linfócitos infiltrantes de tumor, processo para preparação de uma população de linfócitos infiltrantes de tumor, população de linfócitos infiltrantes de tumor, e, composição farmacêutica.
US20200224161A1 (en) 2017-05-10 2020-07-16 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
EP3714041A1 (en) 2017-11-22 2020-09-30 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
EP3724885A2 (en) 2017-12-15 2020-10-21 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
CA3090795A1 (en) 2018-02-13 2019-08-22 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
US20220133795A1 (en) 2019-03-01 2022-05-05 Iovance Biotherapeutics, Inc. Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof
CA3134144A1 (en) 2019-03-29 2020-10-08 Myst Therapeutics, Llc Ex vivo methods for producing a t cell therapeutic and related compositions and methods
CA3162703A1 (en) 2019-11-27 2021-06-03 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
JP7817937B2 (ja) 2020-02-27 2026-02-19 ターンストーン バイオロジクス コーポレイション 腫瘍反応性ｔ細胞のエクスビボ富化および増大のための方法ならびに関連するその組成物
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2026044087A1 (en) 2024-08-21 2026-02-26 Shape Therapeutics Inc. Increased cellular stability for aav production
WO2026073032A1 (en) 2024-09-27 2026-04-02 Shape Therapeutics Inc. Constructs for improved aav production

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486344A (en) * 1983-03-28 1984-12-04 Miles Laboratories, Inc. Urea-linked immunogens, antibodies, and preparative method
DK354487A (da) * 1986-07-11 1988-01-12 Noboru Yanaihara Oncogen-relaterede peptider
PT90657B (pt) * 1988-05-27 1995-03-01 Ortho Pharma Corp Processo para a preparacao de peptidos que bloqueiam a ligacao de hiv-1 a proteina cd4 receptora
WO1991015224A1 (en) * 1990-03-30 1991-10-17 Smithkline Beecham Corporation Inhibition of disease associated with immunodeficiency virus infection
CA2067031C (en) * 1991-04-26 2003-02-18 Shigekazu Nagata Dna coding for human cell surface antigen
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof
NZ275711A (en) * 1993-10-14 1998-03-25 Immunex Corp Monoclonal antibodies and binding proteins which bind to human fas antigen (nerve growth factor/tumour necrosis factor receptor type)

Also Published As

Publication number Publication date
EP0705278B1 (de) 2003-11-26
US20070207160A1 (en) 2007-09-06
JP3778453B2 (ja) 2006-05-24
ATE255129T1 (de) 2003-12-15
DK0705278T3 (da) 2004-03-22
DE4447484A1 (de) 1995-10-26
ES2211899T3 (es) 2004-07-16
EP0705278A1 (de) 1996-04-10
JP2004215669A (ja) 2004-08-05
WO1995027735A1 (de) 1995-10-19
JP3811745B2 (ja) 2006-08-23
JPH08511692A (ja) 1996-12-10

Similar Documents

Publication Publication Date Title
DE4447484C2 (de) Mittel zur Hemmung von Apoptose
DE69433422T2 (de) Monoklonaler anti-hiv antikörper
DE69229428T2 (de) Therapeutisch nützliche peptide und peptidfragmente
DE69330643T2 (de) Monoklonaler antikörper, welcher spezifisch an vaskularisiertes tumorendothelium bindet und verwendungen davon
DE69522216T2 (de) Zielzellen-bindende chimäre Peptide
DE69431834T2 (de) Für den vorläufer des für die tumorabstossung verantwortlichen antigens mage-3 kodierendes, isoliertes nukleinsäuremolekül und seine verwendung
DE69233153T2 (de) Humanisierte monoklonale antikörper
DE69129896T2 (de) Gegen cd3 gerichtete antikörper
DE69233435T2 (de) Vorläufer von für tumorabstossung verantwortlichen antigenen, die antigene und deren verwendungen
DE60133029T2 (de) Mittel zur prävention oder behandlung von psoriasis mit einem il-6-antagonist als wirkstoff
DE69624436T2 (de) Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie
DE69017753T2 (de) Tumor-Nekrosefaktor-Bindungsprotein II, seine Reinigung und spezifische Antikörper.
DE69334186T2 (de) Vom MAGE-3-Gen en abgeleitetes und von HLA-A1 präsentiertes, isoliertes Nonapeptid und dessen Anwendungen
DE69429095T2 (de) Humanisierte antikoerper
EP0657533A1 (de) Monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen, sowie bispezifische monoklonale Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD-30-HRS-3-Antikorpers
EP1017723A2 (de) Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung
EP1003786A1 (de) Peptid mit radioprotektiver wirkung
DE69131426T2 (de) Neue wasserlösliche polypeptide mit hoher affinität für alpha- und beta- interferone
DE69636170T2 (de) Monoklonaler antikörper, der spezifisch mit dem fas-liganden reagiert, und verfahren zu seiner herstellung
DE68925199T2 (de) Peptide und polypeptide stammend von den submaxillaren drüsen der ratte, deren entsprechende monoklonale und polyklonale antikörper entsprechende hybridomen und verwendung dieser verbindungen in der diagnose bei bestimmungen und für pharmazeutische zwecke
DE69420251T2 (de) Löslicher Interferon-Rezeptor, seine Herstellung und Anwendung
DE69031914T2 (de) Rezeptor für granulozyten-macrophagen-koloniestimulierungsfaktor und seine derivate
WO2001051644A2 (de) ANTI-CD3-EINZELKETTEN-ANTIKÖRPER MIT HUMANEN Cν3- und Cν4- DOMÄNEN
DE69020112T2 (de) Spezifische bindende Wirkstoffe.
DE69131253T2 (de) Zur behandlung von tumoren und hiv-infektionen nützliches pflanzliches protein

Legal Events

Date Code Title Description
AC Divided out of

Ref country code: DE

Ref document number: 4412177

Format of ref document f/p: P

OP8 Request for examination as to paragraph 44 patent law
AC Divided out of

Ref country code: DE

Ref document number: 4412177

Format of ref document f/p: P

AC Divided out of

Ref country code: DE

Ref document number: 4412177

Format of ref document f/p: P

D2 Grant after examination
8364 No opposition during term of opposition
R071 Expiry of right
R071 Expiry of right